百济神州公告公司产品百悦泽(泽布替尼胶囊)的3期临床研究MANGROVE(BGB-3111-306;NCT0400229

智通财经
Jun 30
百济神州公告公司产品百悦泽(泽布替尼胶囊)的3期临床研究MANGROVE(BGB-3111-306;NCT04002297)取得积极结果。该研究旨在评估百悦泽联合利妥昔单抗对照苯达莫司汀联合利妥昔单抗(BR)用于套细胞淋巴瘤(MCL)成人初治患者一线治疗的效果。MANGROVE是一项全球性、随机、开放性3期临床试验旨在评估百悦泽联合利妥昔单抗对照苯达莫司汀联合利妥昔单抗用于套细胞淋巴瘤成人初治患者治疗的有效性与安全性。该研究在全球176个研究中心入组510例患者。公司计划在即将召开的医学大会上公布MANGROVE研究的完整结果并正与全球监管机构就相关注册申报计划开展沟通计划于2026年下半年进行申报。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10